DICE Therapeutics
Nico Joined DICE Therapeutics in December 2019 as Vice President of Translational Immunology. He spent most of his career at Genentech, a member of the Roche Group, where he most recently oversaw the biology aspects multiple small molecule drug development programs in the immunology space. Under his leadership, several programs advanced molecules into clinical development.
Nico has over 25 years of experience in cytokine biology and has published over 60 research papers, covering both the basic biology of important immune regulatory cytokines (e.g. IL-23, IL-27, IL-31) as well as therapeutic efforts to target important immune cell signaling nodes with small molecules (e.g. JAK1, TYK2, BTK, ITK, NIK, BET, and others).
Prior to joining Genentech, Nico obtained his Ph.D. and did a brief Postdoc at the University of Basel in Switzerland, working on Leptin and Thrombopoietin, two cytokines regulating body fat and blood platelet numbers, respectively.
This person is not in any offices
DICE Therapeutics
At DICE Therapeutics, we design and develop innovative therapies in immunology for patients with debilitating disease. Seeking to create a future where convenient oral medicines with biologic-like efficacy are available to patients with serious medical conditions, we are developing oral alternatives to medicines currently limited to injectable forms. We believe that such pills will be widely appreciated by patients and doctors alike, as they provide a lower bar to entry than biologics, and as oral medicines can easily be co-formulated with other efficacious drugs. The combination of our core technology with additional, unique biophysical insights has enabled DICE to target protein-protein interactions with small molecules. In doing so, DICE has cracked open a previously intractable set of clinically validated therapeutic targets, including Interleukin-17 (IL-17). Our lead program – an orally bioavailable IL-17 antagonist for the treatment of psoriasis – is currently progressing through IND-enabling studies. In parallel, we continue to advance both partnered and internal pipeline drug discovery programs, providing a robust pre-clinical pipeline.